Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Added revision entry v3.4.3 and removed revision v3.4.2 from the site's revision history.
    Difference
    0.0%
    Check dated 2026-03-11T10:22:48.000Z thumbnail image
  2. Check
    20 days ago
    No Change Detected
  3. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was added. The government funding status notice and Revision: v3.4.1 were removed.
    Difference
    0.2%
    Check dated 2026-02-11T02:06:37.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    A government funding lapse notice was added, noting that the NIH Clinical Center is open and status updates can be found at opm.gov. The page was updated to revision v3.4.1, replacing the prior v3.4.0.
    Difference
    0.2%
    Check dated 2026-02-03T23:57:09.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    Added a Show glossary toggle and explicit Last Update Submitted that Met QC Criteria and Last Update Posted fields, and labeled No FEAR Act Data. Updated the page revision to v3.4.0 (from v3.3.4).
    Difference
    0.1%
    Check dated 2026-01-27T23:50:10.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    Revision: v3.3.4 has been added. Revision: v3.3.3 has been removed.
    Difference
    0.0%
    Check dated 2026-01-14T01:29:35.000Z thumbnail image
  7. Check
    84 days ago
    Change Detected
    Summary
    Locations section expanded to include numerous new sites across the United States and internationally, broadening the geographic coverage of the trial.
    Difference
    3%
    Check dated 2025-12-23T09:21:53.000Z thumbnail image

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.